What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
His main research concerns Leukemia, Internal medicine, Myeloid leukemia, Oncology and Myeloid.
Martin S. Tallman has researched Leukemia in several fields, including Acute promyelocytic leukemia, Cancer and Adverse effect.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Surgery.
His Myeloid leukemia research integrates issues from Myelodysplastic syndromes, Enasidenib, Fms-Like Tyrosine Kinase 3 and Cellular differentiation.
The study incorporates disciplines such as Clinical trial, Pharmacology, Transplantation and Cohort in addition to Oncology.
His studies deal with areas such as Daunorubicin and Anthracycline as well as Myeloid.
His most cited work include:
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia (2097 citations)
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel (2002 citations)
- Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. (1818 citations)
What are the main themes of his work throughout his whole career to date?
Martin S. Tallman spends much of his time researching Internal medicine, Oncology, Myeloid leukemia, Leukemia and Cancer research.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery.
His work deals with themes such as Cancer, Clinical trial and Cohort, which intersect with Oncology.
His studies in Myeloid leukemia integrate themes in fields like Enasidenib, Refractory, Intensive care medicine, Stem cell and Disease.
His Leukemia study incorporates themes from Myeloid, Bone marrow and Acute promyelocytic leukemia.
His biological study spans a wide range of topics, including Mutation, Haematopoiesis and Mutant.
He most often published in these fields:
- Internal medicine (71.66%)
- Oncology (41.08%)
- Myeloid leukemia (34.63%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (71.66%)
- Oncology (41.08%)
- Myeloid leukemia (34.63%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Myeloid leukemia, Cancer research and Leukemia.
Arsenic trioxide and Febrile neutropenia is closely connected to Gastroenterology in his research, which is encompassed under the umbrella topic of Internal medicine.
His work on Chemotherapy regimen as part of general Oncology research is frequently linked to In patient, thereby connecting diverse disciplines of science.
His research integrates issues of Clinical trial, Stem cell, Refractory and Isocitrate dehydrogenase in his study of Myeloid leukemia.
His research on Cancer research also deals with topics like
- Cancer, which have a strong connection to Acute leukemia,
- Mutant which connect with Newly diagnosed and Dose escalation.
His Leukemia study combines topics from a wide range of disciplines, such as Acute promyelocytic leukemia and Bone marrow.
Between 2018 and 2021, his most popular works were:
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia (179 citations)
- Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet (134 citations)
- Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. (132 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Internal medicine, Myeloid leukemia, Oncology, Gastroenterology and Cancer research are his primary areas of study.
Martin S. Tallman regularly ties together related areas like Enasidenib in his Internal medicine studies.
The concepts of his Myeloid leukemia study are interwoven with issues in Refractory, Gene mutation, IDH2, IDH1 and Febrile neutropenia.
His research investigates the connection between Oncology and topics such as Chronic lymphocytic leukemia that intersect with problems in Progression-free survival and Cytopenia.
His Cancer research study combines topics in areas such as Allosteric regulation, Haematopoiesis, Combination therapy and Myristoylation.
His work in Leukemia covers topics such as Myeloid which are related to areas like Cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
